Fig. 2From: Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitroKaplan-Meier survival curves in stage II-IIIA NSCLC. Recurrence-free survival was compared according to expression status of cyclin D1 in 372 patients (a), 140 patients with adenocarcinomas (b), and 201 patients with squamous cell carcinomas. P–values were based on the log-rank testBack to article page